Ratings by William Blair (Raju Prasad)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/15/2025 | Verve Therapeutics | VERV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2024 | Pyxis Oncology Inc. | PYXS | Maintain | Market Perform (Outperform) |
|
Details | ||
| 10/3/2022 | LogicBio Therapeutics | LOGC | Downgrade | Market Perform (Outperform) |
0.27 (7.06) |
2514.81% | Details | |
| 8/8/2022 | Global Blood Therapeutics | GBT | Downgrade | Market Perform (Outperform) |
63.84 (68.49) |
7.28% | Details | |
| 6/9/2022 | Precision BioSciences Inc. | DTIL | Downgrade | Market Perform (Outperform) |
2.09 (7.03) |
236.36% | Details | |
| 5/9/2022 | LogicBio Therapeutics | LOGC | Upgrade | Outperform (Market Perform) |
0.50 (0.27) |
-46% | Details | |
| 2/18/2022 | Intellia Therapeutics | NTLA | New Coverage | Outperform (N/A) |
90.40 (25.60) |
-71.68% | Details | |
| 2/3/2022 | LogicBio Therapeutics | LOGC | Downgrade | Market Perform (Outperform) |
1.50 (7.06) |
370.67% | Details | |
| 12/14/2021 | Generation Bio | GBIO | Downgrade | Market Perform (Outperform) |
13.90 (5.34) |
-61.58% | Details | |
| 12/7/2021 | Global Blood Therapeutics | GBT | Upgrade | Outperform (Market Perform) |
28.23 (68.49) |
142.61% | Details | |
| 11/8/2021 | Cellectis | CLLS | Downgrade | Market Perform (Outperform) |
12.23 (2.81) |
-77.02% | Details | |
| 11/2/2021 | Pyxis Oncology Inc. | PYXS | New Coverage | Outperform (N/A) |
13.20 (2.16) |
-83.64% | Details | |
| 10/20/2021 | Beam Inc | BEAM | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2021 | Verve Therapeutics | VERV | Maintain | Outperform (N/A) |
|
Details | ||
| 9/2/2021 | Assembly Biosciences | ASMB | Downgrade | Market Perform (Outperform) |
3.80 (27.19) |
615.53% | Details | |
| 8/10/2021 | bluebird bio | BLUE | New Coverage | Market Perform (N/A) |
25.03 (4.97) |
-80.14% | Details | |
| 7/12/2021 | Verve Therapeutics | VERV | New Coverage | Outperform (N/A) |
46.00 (11.13) |
-75.8% | Details | |
| 6/8/2021 | bluebird bio | BLUE | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/12/2021 | Selecta Biosciences | SELB | Upgrade | Outperform (Market Perform) |
3.90 (0.88) |
-77.44% | Details | |
| 2/25/2021 | Global Blood Therapeutics | GBT | Downgrade | Market Perform (Outperform) |
49.19 (68.49) |
39.24% | Details | |
| 2/24/2021 | Generation Bio | GBIO | New Coverage | Outperform (N/A) |
37.18 (13.90) |
-62.61% | Details | |
| 2/24/2021 | Taysha Gene Therapies | TSHA | New Coverage | Outperform (N/A) |
29.10 (6.95) |
-76.12% | Details | |
| 2/16/2021 | bluebird bio | BLUE | Downgrade | Market Perform (Outperform) |
45.76 (4.97) |
-89.14% | Details | |
| 11/2/2020 | bluebird bio | BLUE | Upgrade | Outperform (Market Perform) |
51.71 (45.76) |
-11.51% | Details | |
| 8/5/2020 | Beam Inc | BEAM | New Coverage | Outperform (N/A) |
19.41 (35.55) |
83.15% | Details | |
| 7/31/2020 | Alexion Pharmaceuticals | ALXN | Downgrade | Market Perform (Outperform) |
104.60 (182.01) |
74.01% | Details | |
| 2/25/2020 | Precision BioSciences Inc. | DTIL | New Coverage | Outperform (N/A) |
8.24 (7.03) |
-14.68% | Details | |
| 12/9/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2019 | CRISPR Therapeutics | CRSP | Upgrade | Outperform (Market Perform) |
58.53 (54.90) |
-6.2% | Details | |
| 9/26/2019 | Alexion Pharmaceuticals | ALXN | New Coverage | Outperform (N/A) |
100.40 (182.01) |
81.28% | Details | |
| 9/19/2019 | bluebird bio | BLUE | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/12/2019 | bluebird bio | BLUE | Downgrade | Market Perform (Outperform) |
125.23 (4.97) |
-96.03% | Details | |
| 3/14/2019 | Cellectis | CLLS | New Coverage | Outperform (N/A) |
18.71 (12.23) |
-34.63% | Details | |
| 3/14/2019 | CRISPR Therapeutics | CRSP | New Coverage | Market Perform (N/A) |
39.41 (58.53) |
48.52% | Details | |
| 3/14/2019 | Allogene | ALLO | New Coverage | Outperform (N/A) |
26.72 (2.10) |
-92.14% | Details | |
| 3/7/2019 | Spark Therapeutics | ONCE | Downgrade | Market Perform (Outperform) |
113.70 (110.05) |
-3.21% | Details | |
| 1/17/2019 | Loxo Oncology | LOXO | Downgrade | Market Perform (Outperform) |
233.26 (234.80) |
0.66% | Details | |
| 11/13/2018 | LogicBio Therapeutics | LOGC | New Coverage | Outperform (N/A) |
15.11 (7.06) |
-53.28% | Details | |
| 11/7/2018 | Audentes Therapeutics | BOLD | Downgrade | Market Perform (Outperform) |
29.13 (2.69) |
-90.77% | Details | |
| 10/30/2018 | Celyad SA | CYAD | New Coverage | Outperform (N/A) |
23.58 (0.47) |
-98.01% | Details | |
| 9/26/2018 | Krystal Biotech | KRYS | Maintain | Outperform (N/A) |
|
Details |
